RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Paul Wang to Doxorubicin

Back to Details
This is a "connection" page, showing publications Paul Wang has written about Doxorubicin.
Paul Wang
Connection Strength
0.067
Doxorubicin
  1. Tuguntaev RG, Chen S, Eltahan AS, Mozhi A, Jin S, Zhang J, Li C, Wang PC, Liang XJ. P-gp Inhibition and Mitochondrial Impairment by Dual-Functional Nanostructure Based on Vitamin E Derivatives To Overcome Multidrug Resistance. ACS Appl Mater Interfaces. 2017 May 24; 9(20):16900-16912.
    View in: PubMed
    Score: 0.036
  2. Zhao Y, Chen F, Pan Y, Li Z, Xue X, Okeke CI, Wang Y, Li C, Peng L, Wang PC, Ma X, Liang XJ. Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance. ACS Appl Mater Interfaces. 2015 Sep 02; 7(34):19295-305.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support